Nostrum Laboratories: Liquidation and ANDA Portfolio Sale

Nostrum Laboratories, Inc., a Kansas City, Missouri-based generic drug manufacturer, filed for chapter 11 protection on September 30, 2024, in the U.S. Bankruptcy Court for the District of New Jersey. Law360 reported the filing with nearly 68.3 million in debt, about a year after the company agreed to a Department of Justice settlement over Medicaid rebate allegations. The DOJ said the settlement required a minimum payment of $3.825 million and up to 50 million in total payments.

Nostrum was already widely known for its pricing decisions around nitrofurantoin oral suspension, a bladder infection antibiotic. CNN reported that the company raised the price of the drug from about $475 to about $2,393 per bottle in 2018, an increase of more than 400%. STAT News reported that the company's CEO, Nirmal Mulye, described the price increase as a "moral requirement" to make money, drawing public criticism from medical groups and regulators.

The chapter 11 case unfolded as a liquidation that monetized the company's ANDA portfolio, equipment, and real property, while the debtor operated on a cash collateral budget and a small, payroll-focused DIP facility. Court filings show that the debtor employed about 94 workers at petition, operated manufacturing sites in Kansas City and Ohio, and relied on Citizens Bank for secured financing. The auction process culminated in a multi-buyer sale on April 1, 2025, and Law360 reported that the official committee of unsecured creditors was authorized to join sale efforts.

Outside the courtroom, the company faced product quality and operational wind-down issues. Fierce Pharma reported that Nostrum ceased operations and terminated operational employees at all domestic U.S. sites in 2024. The FDA issued a recall notice for Sucralfate Tablets USP 1 gram, covering all lots within expiry manufactured after June 2023. The recall notice said no adverse events had been reported and instructed that lots should be destroyed rather than returned.

Debtor	Nostrum Laboratories, Inc.
Court	U.S. Bankruptcy Court, District of New Jersey
Case Number	24-19611 (JKS)
Judge	Hon. John K. Sherwood
Petition Date	September 30, 2024
Headquarters	Kansas City, Missouri Kansas City facility address
Facilities	Kansas City, MO and Ohio (manufacturing)
Industry	Pharmaceutical manufacturing
Products	12+ drugs marketed or distributed in the U.S.
Employees (prepetition)	About 94 employees (petition-date workforce)
Estimated Debt	Approximately $68.3 million
Secured Lender	Citizens Bank, N.A.
DIP Facility	Up to $235,000, limited to payroll
DIP Interest	8%
Investment Banker	Raymond James & Associates, Inc.
Auction Date	April 1, 2025
Sale Hearing	April 8, 2025
Medicaid Settlement (2023)	Up to $50 million

Restructuring and Asset Sale Process

Case strategy and scope. Nostrum entered chapter 11 as a single-debtor case with a liquidation strategy centered on selling its ANDA portfolio, manufacturing equipment, and real property. The process reflected a business that was not positioned to fund a long reorganization. Court filings show no confirmed plan or disclosure statement in the record excerpts reviewed, and the case proceeded through cash collateral orders, a small DIP facility, and a structured auction.

Cash collateral and payroll stabilization. Early in the case, the debtor sought authority to use cash collateral to cover payroll-related obligations. Court filings show a petition-date workforce of about 94 employees across two manufacturing facilities, with monthly gross payroll around $432,000 and about $274,000 in prepetition payroll-related obligations. The debtor used cash collateral under an initial 13-week budget and rolling four-week updates, with reporting requirements that included weekly cash reporting and monthly borrowing base certificates. Adequate protection included monthly interest payments to the prepetition lender, replacement liens on postpetition collateral, and a carve-out for U.S. Trustee fees and capped professional fees.

The payroll motion also outlined the structure of the workforce and the scale of employee-related obligations. Court filings show that the workforce included roughly 92 full-time employees and one part-time employee, with an additional group of independent contractors. About 53 associates were paid on an hourly basis and about 41 were paid on a salaried basis, with most employees on a bi-weekly payroll cycle. The debtor estimated unpaid prepetition wages of about $250,000, withholding and deduction obligations of about $72,000, and non-executive 401(k) contributions of about $25,000, all of which underpinned the request to use cash collateral for payroll continuity.

Workforce Metric	Detail
Facilities	Kansas City, MO and Ohio manufacturing sites
Total employees	About 94
Full-time / part-time	About 92 full-time and 1 part-time
Hourly / salaried	About 53 hourly and 41 salaried
Pay cycle	Mostly bi-weekly
Monthly gross payroll	About $432,000
Prepetition payroll obligations	About $274,000 total

DIP financing limited to payroll. By April 2025, the debtor secured a stipulated DIP facility of up to $235,000 at 8% interest. Court filings describe the DIP loan as an advance under the prepetition credit documents and limited in use to a defined payroll period, with restrictions on insider payments without lender consent. The small size and limited purpose of the DIP facility indicates the case was centered on closing payroll obligations and completing the asset sale process rather than funding a long-term operating reorganization.

DIP and Cash Collateral Term	Detail
DIP lender	Citizens Bank, N.A.
DIP size	Up to $235,000
DIP interest	8%
DIP maturity	Earliest of April 30, 2025, plan confirmation, or conversion/dismissal
DIP use	Limited to specified payroll period; no insider payments without consent
Cash collateral budget	13-week budget with rolling four-week updates
Adequate protection	Monthly interest payments and replacement liens
Superpriority	Section 364(c)(1) DIP superpriority claim and 507(b) protections

The cash collateral framework was built around tight reporting and lender protections. Court filings show weekly cash reporting and periodic borrowing base certificates, with monthly interest payments to the prepetition lender as adequate protection. The debtor also agreed to replacement liens on postpetition collateral and superpriority claims for any diminution in value. The carve-out structure preserved funds for U.S. Trustee fees and capped professional fees, which is typical in a case where the secured lender provides the primary liquidity. Taken together, the cash collateral conditions and the limited DIP size underscored the case's focus on preserving value during a sale process rather than funding new operations.

Sale process and committee role. The court entered bidding procedures on February 14, 2025, setting an auction for April 1, 2025 and a sale hearing for April 8, 2025. The auction began at 10:00 a.m. and continued into the night, with multiple buyers winning separate asset packages. Law360 reported that the official committee of unsecured creditors was authorized to participate with the investment banker in the sale process.

Court filings describe a multi-asset process that separated ANDAs, manufacturing equipment, and real property into distinct packages, allowing multiple buyers to compete for specific assets. The auction produced a mix of cash sales and a credit bid for the Ohio real property. The result was a multi-buyer allocation of ANDAs and facilities rather than a single going-concern transaction, a structure consistent with a wind-down and the limited scale of the debtor's postpetition payroll funding.

Date	Event
September 30, 2024	Chapter 11 petition filed
October 9, 2024	Interim cash collateral order entered
December 11, 2024	Final cash collateral order entered
February 14, 2025	Bidding procedures order entered
April 1, 2025	Auction held (10:00 a.m. to approximately midnight)
April 8, 2025	Sale hearing
April 17, 2025	Stipulated DIP financing order entered

Buyer	Assets	Consideration
Chartwell Pharmaceuticals	ANDAs	$4,625,000
Strides Pharma	4 ANDAs	2.075 million
Everest	ANDAs and Kansas City facility component	$1,900,000
Everest (second package)	One ANDA	$275,000
ANI	ANDAs	$1,700,000
Solis	ANDAs	$1,225,000
Aviv	ANDAs	$600,000
PAI	ANDAs	$350,000
Big Shoulders	ANDAs	$250,000
Bion	ANDAs	$50,000
Waterford	Ohio real property (credit bid)	$1,345,085
Kesin (backup)	One ANDA	$150,000

Court filings show total proceeds from the auction exceeded $14.3 million when aggregating the successful bids. The structure separated ANDAs into multiple packages, allowing buyers to pursue specific molecules or product groups rather than requiring a single buyer to absorb the full portfolio. Several bids focused on ANDA packages only, while others paired regulatory assets with facilities or equipment. The Waterford credit bid for Ohio real property, together with smaller ANDA packages sold to Aviv, PAI, Big Shoulders, and Bion, illustrates a liquidation approach designed to maximize recovery from individual assets rather than preserve an integrated manufacturing platform.

Strides portfolio details. Indian Pharma Post reported that Strides Pharma acquired four approved ANDAs for $2.075 million and said the portfolio covered liquids and solid oral products across therapeutic areas including urinary tract infections, pain management, allergy symptoms, and ADD/ADHD, with an estimated market size of about $57 million based on IQVIA data.

Sale closing terms. Court filings indicate that sales were structured as transfers free and clear of liens, with contract assumptions and cure amounts subject to adjustment at closing. The use of back-up bids for certain assets, such as a $150,000 back-up bid for one ANDA, provided procedural protection for closing risk and pricing certainty.

Ohio facility sale resolution. Law360 reported court approval of a 1.75 million sale of the Ohio drug facility and noted an agreement with the buyer and lenders on the costs of removing controlled substances.

Operations and Product Portfolio

Business profile. Nostrum Laboratories is a generic pharmaceutical manufacturer with operations based in Kansas City, Missouri, and the company lists its Kansas City facility address on its contact page. Business profile sources describe a focus on formulation and commercialization of specialty pharmaceutical products, including controlled-release, orally administered, branded, and generic drugs. See company profile details and specialty product focus. Court filings in the chapter 11 case report a petition-date workforce of about 94 employees.

Facilities and workforce. Court filings describe two manufacturing facilities, one in Kansas City and one in Ohio, and a workforce of about 94 employees as of the petition date. Those filings also describe a workforce mix of mostly full-time employees, a smaller part-time cohort, and a combination of hourly and salaried associates. The operational footprint aligns with a manufacturer focused on a targeted portfolio of generic products rather than a large multi-site platform.

In public statements before the bankruptcy, Mulye described economic pressure in the generic drug business. CNBC reported that he said the company lost money in eight of eleven years and argued that FDA review timelines created margin pressure. Those comments do not establish a causal link to the bankruptcy, but they provide context for how management viewed the economics of a small generic manufacturer operating with a limited product portfolio.

Product scope. Public drug listings show that Nostrum markets or distributes more than 12 drugs in the United States, with product offerings that include acetazolamide, metformin hydrochloride, and venlafaxine hydrochloride. DrugBank lists nitrofurantoin as an FDA-approved drug first approved on February 6, 1953, and identifies it as a World Health Organization essential medicine. The company's pricing decisions around nitrofurantoin became a national focal point in 2018 and were later cited in broader reporting around the company's regulatory exposure.

Product	Use or Context	Source
Nitrofurantoin oral suspension	Bladder and urinary tract infections	CNN description
Sucralfate Tablets USP 1 gram	Ulcer treatment; subject to recall	FDA recall notice
Metformin hydrochloride	Referenced in NDMA recall coverage	Fierce Pharma report

Metric	Detail
Headquarters	Kansas City, Missouri
Facilities	Kansas City, MO and Ohio
Employees (petition date)	About 94
Monthly gross payroll	About $432,000
Product portfolio	12+ drugs, including nitrofurantoin oral suspension

Drug Pricing Controversy and Public Response

2018 price increase. In August 2018, the company increased the price of nitrofurantoin oral suspension by more than 400%. CNN reported the price increase from about $475 to about $2,393 per bottle. STAT News reported a similar increase and described the product as a generic liquid antibiotic used for bladder infections.

Executive statements. In public interviews around the price increase, CEO Nirmal Mulye stated that he had a "moral requirement" to make money. CNBC reported that Mulye argued the generic drug business lost money in eight of eleven years and criticized FDA inefficiencies in the approval process.

Industry and regulatory responses. The price increase drew criticism from infectious disease organizations. Healio reported that the Infectious Diseases Society of America and the HIV Medicine Association criticized the pricing move and noted that Nostrum was the only manufacturer of the liquid formulation at the time. BioPharma Dive reported that then-FDA Commissioner Scott Gottlieb responded publicly, stating there was "no moral imperative" to price gouge.

DrugBank lists nitrofurantoin as an FDA-approved drug first approved in 1953 and on the World Health Organization essential medicines list. Local reporting said Mulye argued the price increase was still below a competitor price of $2,800 per bottle, describing $2,300 as a bargain. Together these details show how a widely used legacy drug, with a single manufacturer for the liquid formulation, became the focal point of the pricing dispute.

Date	Pricing-Related Event	Source
February 6, 1953	FDA approval date for nitrofurantoin	DrugBank
August 2018	Price increase to about $2,393 per bottle	CNN report
September 2018	FDA Commissioner response to pricing claims	BioPharma Dive

Local impact and jobs. Local reporting in Kansas City described Nostrum's presence in the East Bottoms neighborhood and included statements from Mulye about potential job impacts. The Pitch reported that the company operated in Kansas City's East Bottoms and that Mulye warned criticism could jeopardize about 100 jobs at the plant.

Medicaid Settlement and Regulatory Exposure

False Claims Act settlement. In November 2023, the U.S. Department of Justice announced that Nostrum and CEO Nirmal Mulye agreed to pay a minimum of $3,825,000 and up to 50 million to resolve allegations that the company underpaid Medicaid drug rebates. The DOJ statement said the allegations involved Nitrofurantoin Oral Suspension and claimed the company knowingly underpaid Medicaid rebates by improperly calculating the amounts owed.

The DOJ release described allegations that the company reformulated Nitrofurantoin Oral Suspension and then underpaid rebates tied to the new formulation. The FBI statement in the release said the company reduced the amount it paid to Medicaid by "improperly calculating the rebates." The settlement framework, with a minimum payment and a capped maximum, created a contingent liability that sat alongside secured debt and other trade and operational obligations.

Timing relative to the filing. Law360 reported that the chapter 11 filing came about a year after the settlement. The settlement added a material liability while the company was already under financial pressure from its capital structure and operational challenges.

Regulatory context. The settlement followed a period of scrutiny related to drug pricing and rebate compliance. Public reporting tied the nitrofurantoin pricing decision to the broader debate over generic drug pricing. That regulatory exposure did not, by itself, determine the chapter 11 outcome, but it remains a documented part of the background to the filing.

Settlement Element	Detail
Minimum payment	$3,825,000
Maximum payment	$50,000,000
Drug referenced	Nitrofurantoin Oral Suspension (Nitro OS)
Allegations	Underpayment of Medicaid rebates

Prepetition Capital Structure and Lender Dispute

Secured lender facilities. Court filings show that Citizens Bank, N.A. (through its predecessor Investors Bank) provided three prepetition credit facilities: a $5 million line of credit and term loan, a $12 million revolving line of credit, and a $5 million term loan. The loans were secured by a security interest in substantially all personal property, including accounts, inventory, equipment, intellectual property, and deposit accounts, along with a pledge of certain bonds. The security interest was perfected by a UCC-1 financing statement filed on December 31, 2020.

The collateral package described in the filings covered operating assets that typically support a manufacturing business: inventory, equipment, accounts receivable, trademarks, and other intangible property. That breadth matters in a liquidation case because it determines how sale proceeds are allocated between secured and unsecured creditors and why cash collateral use required lender consent and adequate protection during the case.

Forbearance and acknowledged balance. Court filings indicate that a forbearance agreement dated October 31, 2022 required the debt to be paid in full by December 31, 2022. As of the forbearance date, Nostrum acknowledged approximately $17,226,584.78 in obligations to Citizens, plus accruing interest, costs, and fees. The dispute with Citizens led to federal litigation, a fiscal agent appointment, and later requests for a receiver before the chapter 11 filing.

The enforcement timeline in court filings includes the execution of loan and security documents in December 2020, the October 2022 forbearance, and litigation initiated in October 2023. Court filings indicate that a fiscal agent was appointed in mid-2024 following a federal court order, and that the lender later sought a receiver shortly before the chapter 11 filing. These steps help frame the bankruptcy as the continuation of a dispute over collateral control, cash collateral use, and oversight of asset sales.

Date	Lender Event	Court Filings
December 31, 2020	Loan agreement and UCC-1 filing	Prepetition credit documents
October 31, 2022	Forbearance agreement	Acknowledged $17.226 million balance
October 6, 2023	Citizens litigation filed	Prepetition enforcement action
June 27, 2024	Federal court order appointing fiscal agent	Prepetition oversight
July 29, 2024	Fiscal agent appointment effective	Prepetition oversight
September 24, 2024	Receiver request granted in federal court	Prepetition enforcement

Total debt at filing. Law360 reported that Nostrum filed with nearly 68.3 million in debt. This figure reflects the broader debt structure beyond the secured facilities, including liabilities associated with regulatory settlements and trade obligations.

Facility	Original Commitment	Notes
Line of credit and term loan	$5 million	Citizens Bank facility documented in court filings
Revolving line of credit	$12 million	Citizens Bank facility documented in court filings
Term loan	$5 million	Citizens Bank facility documented in court filings

Operational Wind-Down and Product Recalls

Operations shutdown. Fierce Pharma reported that the company ceased operations and terminated operational employees at all domestic U.S. sites in 2024. The shutdown coincided with the liquidation framework in the chapter 11 case and a reduced payroll profile funded by cash collateral and a limited DIP facility.

Sucralfate recall. The FDA issued a recall notice for Sucralfate Tablets USP 1 gram, covering all lots within expiry that were manufactured after June 2023. The FDA notice said the product was distributed to wholesalers, retailers, manufacturers, medical facilities, and repackagers, and that no adverse events had been reported at the time of the recall. The notice instructed that the products should be destroyed and that the company was not accepting returns.

Recall Detail	Description
Product	Sucralfate Tablets USP 1 gram
Scope	All lots within expiry manufactured after June 2023
Distribution	Wholesalers, retailers, manufacturers, medical facilities, repackagers
Adverse events	None reported in FDA notice
Return policy	Destroy all lots; no returns accepted

Quality program and additional recalls. Fierce Pharma reported that Nostrum initiated the Sucralfate recall after discontinuing its quality program and said the company could not assure that product met specifications. The same report referenced earlier industry recalls, including a mass recall of metformin products in 2020 and 2021 due to NDMA findings.

The recall posture is consistent with a company that had shut down operations and could no longer maintain the quality systems required for ongoing manufacturing. The FDA notice instructed downstream customers and distributors to destroy affected lots rather than return them, indicating an end-of-life treatment for existing inventory rather than an ongoing remediation program.

Frequently Asked Questions

What does Nostrum Laboratories make?

Nostrum produces and distributes generic pharmaceuticals, with public listings showing more than 12 drugs in the United States. Business profile sources describe a focus on formulation and commercialization of specialty pharmaceutical products, including controlled-release and orally administered drugs. See company profile details.

When did Nostrum file for chapter 11, and how much debt did it report?

The company filed on September 30, 2024 in the District of New Jersey. Law360 reported that the filing listed nearly $68.3 million in debt.

What happened with the nitrofurantoin price increase?

In 2018, the company raised the price of nitrofurantoin oral suspension from roughly $475 to about $2,393 per bottle, an increase of more than 400%. The price hike drew public criticism and was cited in reporting about the company's broader regulatory exposure.

What was the Medicaid settlement with the Department of Justice?

The DOJ announced in November 2023 that Nostrum and CEO Nirmal Mulye agreed to pay a minimum of $3,825,000 and up to 50 million to resolve allegations that the company underpaid Medicaid rebates for Nitrofurantoin Oral Suspension.

What secured lender financed Nostrum before bankruptcy?

Court filings show Citizens Bank, N.A. as the prepetition secured lender under multiple credit facilities. The obligations were secured by substantially all personal property, and a forbearance agreement documented the outstanding balance as of October 2022.

What DIP financing did the debtor obtain?

Court filings show a DIP facility of up to $235,000 at 8% interest from Citizens Bank, structured as an advance under the prepetition credit documents and limited to a defined payroll period.

How were the assets sold?

The debtor ran a multi-buyer auction on April 1, 2025, selling different ANDA packages, equipment, and real property to multiple buyers. One buyer, Strides Pharma, announced the acquisition of four ANDAs for 2.075 million, with a portfolio that included liquids and solid oral products across several therapeutic categories.

What happened to operations and product quality?

Fierce Pharma reported that the company ceased operations and terminated operational employees at all domestic U.S. sites, and that it initiated a voluntary recall of Sucralfate Tablets after discontinuing its quality program. The FDA recall notice said no adverse events had been reported and instructed that all lots should be destroyed.

Who is the claims agent for Nostrum Laboratories?

Epiq Corporate Restructuring, LLC serves as the claims and noticing agent. The firm maintains the official claims register and distributes case notifications to creditors and parties in interest.

For more bankruptcy case analyses and restructuring insights, visit ElevenFlo's bankruptcy blog.